Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Manchester_Patrick_1000x714_ENV

Patrick E. Manchester

Partner

Washington +1 202 662 5570

  • About
  • Representative Matters
  • Credentials
  • About

    Patrick Manchester helps clients evaluate, negotiate and implement transactions involving sales and acquisitions of companies and their assets. Patrick’s thoughtful and pragmatic approach to his practice enables clients to achieve their strategic objectives efficiently and effectively, while carefully managing legal risks in order to realize long-term value.

    Patrick is a co-chair of the firm’s medical device industry practice and food and beverage industry practice.

    Patrick’s experience includes:

    • assisting clients in navigating asset and stock acquisitions and sales, public and private company mergers and business combinations, carve-out divestitures, joint ventures and strategic partnerships, and cross-border mergers and acquisitions; and
    • working with clients at all stages of development in a number of industry sectors, particularly the pharmaceutical, medical device and food and beverage industries.

    In addition, Patrick’s practice includes pro bono work with non-profit clients to steer them through significant life cycle events and to advise non-profit boards of directors on governance matters.

    Patrick has been recognized by New York Super Lawyers and Washington, DC Super Lawyers as a “Rising Star” in mergers and acquisitions.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • Cameco Corporation in its strategic partnership with Brookfield Renewable Partners to acquire Westinghouse Electric Company in a deal valued at $7.875 billion.
    • Bacardi in its acquisition of Patrón Spirits International AG and its PATRÓN® brand from John Paul DeJoria in a deal valuing the company at $5.1 billion.
    • Novartis in its sale to Bausch + Lomb of a portfolio of “front of eye” ophthalmology products for up to $2.5 billion, including $1.75 billion in upfront cash and up to $750 million of milestone payments.
    • Alexion, AstraZeneca Rare Disease, in its entry into a definitive purchase and license agreement for a portfolio of preclinical gene therapy programs and enabling technologies from Pfizer for total consideration of up to $1 billion, plus tiered royalties on sales.
    • Central European Media Enterprises, a media and entertainment company operating in five Central and Eastern European markets, in its $2.1 billion acquisition by an affiliate of PPF Group.
    • Merck in its acquisition of Peloton Therapeutics for $1.05 billion upfront and up to $1.15 billion in additional contingent consideration.
    • Boehringer Ingelheim in:
      • the sale of its Newport Laboratories subsidiary, which manufactures and sells custom-made swine and cattle vaccines, to an affiliate of Vaxxinova International;
      • the acquisition of Abexxa Biologics, a biopharmaceutical company focused on the fields of immuno-oncology and oncology research;
      • a series of antitrust-driven divestitures of a portfolio of animal health products and a manufacturing facility in connection with Boehringer’s acquisition of Merial (Sanofi’s animal health business); and
      • the $300 million sale of its Bedford Laboratories generic sterile injectables business to Hikma Pharmaceuticals.
    • Eaton Corporation in its $1.65 billion acquisition of Tripp Lite, a leading supplier of power quality products and connectivity solutions.
    • Medartis in its acquisition of Nextremity Solutions, a medical device company with a focus on the extremity musculoskeletal space.
    • A global company in connection with a strategic investment in the Canadian cannabis industry.

    • Elanco Animal Health in:
      • a series of antitrust-driven divestitures of animal health products in Europe, Australia and New Zealand in connection with Elanco’s acquisition of Bayer Animal Health; and
      • the sale of its Posilac business and manufacturing facility in Augusta, GA to Brazilian company Union Agener.
    • TE Connectivity in the $325 million sale of its subsea communications business to an affiliate of Cerberus Capital Management.
    • Salix Pharmaceuticals in its $2.6 billion acquisition of Santarus.
    • Allergan (formerly Forest Laboratories) in:
      • its $1.1 billion acquisition of Furiex Pharmaceuticals; and
      • its $1.2 billion acquisition of Clinical Data.
    • Omthera Pharmaceuticals in its acquisition by AstraZeneca for $323 million upfront and up to $120 million in additional contingent consideration.
    • King Pharmaceuticals in its $3.6 billion acquisition by Pfizer.
    • Stryker Corporation in:
      • its acquisition of the CareFusion vertebral compression fracture product portfolio from Becton Dickinson; and
      • its acquisition of Muka Metal, A.S., a company based in Kayseri, Turkey that sells hospital beds, stretchers and related patient room furniture and accessories.
    • ITOCHU in the sale of its PrimeSource Building Products subsidiary to an affiliate of Platinum Equity.

    Areas of Expertise

  • Credentials
    Education
    • Georgetown University Law Center, J.D., 2010
        • magna cum laude
        • Order of the Coif
        • Georgetown Law Journal, Notes Editor
    • Duquesne University, B.S., 2007
        • summa cum laude
    Bar Admissions
    • District of Columbia
    • New York
    Languages
    • French

    Areas of Expertise

News and Insights

Events